To provide novel agents that inhibit the binding of Kallidin and des-Arg10-Kallidin to the bradykinin B1 receptor for use in treatment of bradykinin B1 receptor-mediated human pathologies.SOLUTION: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions containing the antibodies, and nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors, and host cells for making such antibodies or fragments thereof. Methods of using the antibodies to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg-Kallidin-like peptide.SELECTED DRAWING: None
